Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 47Neoplasms 10Prostatic Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms, Male 5Sarcoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Sarcoma × ixabepilone × Clear all
NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡